Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome [Seeking Alpha]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Summary STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. Despite recent stock gains, I may consider investing when Phase 3 trial enrollment is announced, given the promising genetic approach to Dravet Syndrome. your_photo/iStock via Getty Images I covered Stoke Therapeutics ( NASDAQ: STOK ) thrice in the last few years. If you read those articles, you will see I have held divergent views about this company over the years. First, I held the view that STOK was overvalued when it had a market cap of $1.88bn - the stock is down 73% since then; then, 3 years later, I thou
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.MarketBeat
- Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet SyndromeBusiness Wire
- Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business OfficerBusiness Wire
- Stoke Therapeutics to Present at Upcoming Investor Conferences in SeptemberBusiness Wire
- Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeBusiness Wire
STOK
Earnings
- 8/7/24 - Beat
STOK
Sec Filings
- 9/23/24 - Form 4
- 9/23/24 - Form SC
- 9/19/24 - Form 144
- STOK's page on the SEC website